BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 31735634)

  • 1. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Abdelfattah NS; Lei J; Shi Y; Marion KM; Morgenthien E; Gune S; Balasubramanian S
    Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S; Abdelfattah NS; Karamat A; Balasubramanian S; Marion KM; Morgenthien E; Sadda SR
    Ophthalmology; 2020 Apr; 127(4):523-532. PubMed ID: 31718842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Khurana RN; Hill L; Ghanekar A; Gune S
    Ophthalmol Retina; 2020 Nov; 4(11):1054-1058. PubMed ID: 32353536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis.
    Khurana RN; Chang LK; Hill LF; Ghanekar A; Stoilov I
    Ophthalmol Retina; 2020 Jan; 4(1):13-18. PubMed ID: 31416763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
    Inan S; Polat O; Karadas M; Inan UU
    Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
    [No Abstract]   [Full Text] [Related]  

  • 12. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.
    Schmidt-Erfurth U; Bogunovic H; Sadeghipour A; Schlegl T; Langs G; Gerendas BS; Osborne A; Waldstein SM
    Ophthalmol Retina; 2018 Jan; 2(1):24-30. PubMed ID: 31047298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
    Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
    Staurenghi G; Cozzi M; Sadda S; Hill L; Gune S
    Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.